Saiyed Atiq Raza

Director Saiyed Atiq Raza sold 70.0K shares at blended average of $36.02 in 2 transactions via scheduled 10b5-1 plan

Saiyed Atiq Raza (Director) executed 2 separate sales totaling 70,000 shares for $2,521,103.16 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, reducing his holdings from 210,000 to 140,000 shares (-33.3%). The transactions were scheduled, not discretionary. At Arteris, Inc.'s fundamentals show the company generated $22.9M in quarterly revenue with $-8.0M net income, and was unprofitable over the most recent full fiscal year. The stock's 30-day return of +29.8% and 90-day return of +140.8% show strong recent appreciation. His prior 5 trades at this ticker have exhibited mixed post-transaction outcomes (ranging from +2.0% to +57.7% in 30-day windows, and +32.1% to +123.0% in 90-day windows), with no clear directional signal. Since this sale is governed by a pre-arranged plan, the timing and sequencing reflect the plan's schedule rather than a discretionary market signal.

Director Raza Saiyed Atiq sells roughly one-third of holdings at stock's 52-week peak

Raza Saiyed Atiq, a director at Arteris, sold a large block representing about 30% of his total stake while the stock is trading near its 52-week high—a timing that stands out because insider selling at peaks often signals caution about near-term valuation. However, the company's fundamentals complicate the picture: Arteris is unprofitable with substantial recent losses, yet revenue is growing double-digits year-over-year. The stock has surged dramatically over the past three months, which could explain why a director would choose to trim a significant position at current levels rather than hold through a period of strong momentum. This sale alone doesn't constitute a red flag, but it warrants attention in context of the company's ongoing path to profitability and whether other insiders or board members follow suit.

Director Raza Saiyed Atiq sells 90,000 shares (23.1% of holdings) for $1,994,353.89 at Arteris Inc. (AIP)

Director Raza Saiyed Atiq executed 2 separate sales totaling 90,000 shares (90.0K shares) for $1,994,353.89 ($2.0M) between April 17–20, 2026, at a blended average price of $22.16. This represents a 23.1% reduction of his pre-transaction holdings from 390,000 shares (390.0K shares) to 300,000 shares (300.0K shares). The sales occurred after a recent 55.8% surge in the stock price over the prior 30 days and at the 52-week high of $23.58. In terms of timing context, his prior trades at AIP show mixed outcomes: 3 of 5 prior sales were followed by negative 30-day returns, though none have measurable 90-day outcomes yet; his cross-ticker track record across 5 prior sells shows an average 30-day return of -0.1%. The company remains unprofitable (net income $-9.0M against quarterly revenue of $17.4M) despite 22.3% annual revenue growth. A substantial director stake reduction following sharp recent appreciation in an unprofitable growth-stage company warrants investor attention to the underlying drivers of this liquidation.

Director Raza Saiyed Atiq sold 109,721 shares at blended average $17.21 for $1.9M, reducing stake 22.0%

Director Raza Saiyed Atiq executed 2 separate sales totaling 109,721 shares for $1,887,866.25 over two days (2026-03-02 and 2026-03-04), reducing his holdings from 499,721 shares to 390,000 shares, a 22.0% reduction in stake. The sales occurred at blended average price $17.21, above the current price of $16.46. Arteris remains unprofitable (net income of -$8,991,000.00 in the latest quarter) despite 22.3% annual revenue growth, and the director filed three separate sells within the preceding week (2026-02-25, 2026-02-26, 2026-02-27) with outcomes still unmeasurable. The concentrated selling pattern over a narrow time window, combined with the company's ongoing losses, merits attention to whether this represents a material shift in the director's confidence in the company's path to profitability.

Director RAZA SAIYED ATIQ sold 90,279 shares over 3 days (Feb 25-27) for $1,545,259.59; stock at $16.99 vs $17.12 blended sale price.

Director RAZA SAIYED ATIQ executed 3 separate sales totaling 90,279 shares for $1,545,259.59 across February 25–27, 2026, at prices ranging from $17.00 to $17.14 (blended average $17.12). Post-transaction holdings of 499,721 shares represent a 15.3% reduction from the 590,000-share pre-transaction position. The timing occurs in a context where the stock has rallied 5.4% over the past 30 days and 18.5% over 90 days from prior lows, yet trades 13.6% below its 52-week high of $19.67. Arteris is generating material revenue ($17.4M latest quarter, +22.3% annual growth) but remains unprofitable on a full-year basis (net income $-9.0M). The multi-day sale pattern, moderate scale relative to total holdings, and price action near recent lows suggest a deliberate liquidation rather than opportunistic single-day execution.